Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for parkinson disease

American Journal of Therapeutics

Volumn 21, Issue 4, 2014, Pages

  El Okdi, Nasser Samir ^a   Lumbrezer, Daniel ^a   Karanovic, Djuro ^a   Ghose, Abhimanyu ^a   Assaly, Ragheb ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

deep brain stimulator; Parkinson disease; serotonin syndrome; tramadol; ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NORADRENALIN; SEROTONIN; SEROTONIN 1A AGONIST; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ARTICLE; BINDING AFFINITY; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; DEEP BRAIN STIMULATOR; HUMAN; IMPLANTABLE NEUROSTIMULATOR; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SEROTONIN SYNDROME; SEROTONIN UPTAKE; SUBTHALAMIC NUCLEUS; BRAIN DEPTH STIMULATION; CHEMICALLY INDUCED; DRUG INTERACTION; METABOLISM; PROCEDURES;

AGED; ANALGESICS, OPIOID; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEEP BRAIN STIMULATION; DRUG INTERACTIONS; HUMANS; MALE; PARKINSON DISEASE; PIPERAZINES; SEROTONIN; SEROTONIN SYNDROME; THIAZOLES; TRAMADOL;

EID: 84904263557     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182456d88     Document Type: Article

References (20)

1. Boyer EW, Shannon M. The serotonin syndrome-current concepts. N Engl J Med. 2005;352:1112-1120.
2. Arora B, Kannikeswaran N. The serotonin syndrome-The need for physician's awareness. Int J Emerg Med. 2010;3:373-377.
3. Watson T, Litovitz T, Rodgers G, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2005;23:589-666.
4. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95: 434-441. (Pubitemid 41418735)
5. Le Roux PJ, Coetzee J. Tramadol today. Curr Opin Anaesthesiol. 2000;13:457-461. (Pubitemid 30623805)
6. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med. 1999;92:474-475. (Pubitemid 29457148)
7. Mahlberg R, Kunz D, Sasse J, et al. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry. 2004;161: 1129.
8. Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60:934-935.
9. Garrett PM. Tramadol overdose and serotonin syndrome manifesting as acute right heart dysfunction. Anaesth Intensive Care. 2004;32:575-577.
10. Selegiline: A second look. Six years later: Too risky in Parkinson's disease. Prescrire Int. 2002;11:108-111.
11. Fernandes C, Reddy P, Kessel B. Rasagiline-induced serotonin syndrome. Mov Disord. 2011;26:766-767.
12. Thebault J, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: A potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004;24:1295-1305. (Pubitemid 39304992)
13. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: A 4-year review of ziprasidone. CNS Spectr. 2005;10(Suppl 17):1-20.
14. Schmidt AW, Lebel LA, Howard HR, et al. Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197-201. (Pubitemid 32770067)
15. Tatsumi M, Jansen K, Blakely RD, et al. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999;368:277-283. (Pubitemid 29117150)
16. Lin PY, Hong CJ. Serotonin syndrome caused by ziprasidone alone. Psychiatry Clin Neurosci. 2010;64:338-339.
17. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355:896-908. (Pubitemid 44315982)
18. Temel Y, Boothman L, Blokland A, et al. Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. Proc Natl Acad Sci U S A. 2007;104:17087-17092. (Pubitemid 350210996)
19. Tan S, Hartung H, Sharp T, et al. Serotonin-dependent depression in Parkinson's disease: A role of the subthalamic nucleus? Neuropharmacology. 2011;61:387-399.
20. Navailles S, Benazzouz A, Bioulac B, et al. High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J Neurosci. 2010;30:2356-2364.